Athira pharma to present additional biomarker data from act-ad phase 2 study of fosgonimeton at the 2022 clinical trials on alzheimer's disease (ctad) conference

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration

ATHA Ratings Summary

ATHA Quant Ranking